{"entity":{"id":"relacorilant","kind":"drug","name":"Relacorilant","aka":[],"tldr":"A first-in-class drug that blocks cortisol signalling in tumour cells, approved in 2026 for platinum-resistant ovarian cancer with chemotherapy.","summary":"Relacorilant is a selective glucocorticoid receptor antagonist that blocks cortisol signalling inside tumour cells, where glucocorticoid receptor activation is a mechanism of chemotherapy resistance, so it restores sensitivity to the taxane given alongside it. Corcept's ROSELLA phase 3 trial showed that relacorilant plus nab-paclitaxel improved both progression-free and overall survival versus nab-paclitaxel alone, and it was approved in Q1 2026 for platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, the first drug in its class. It is taken as 150 mg the day before, the day of and the day after each weekly nab-paclitaxel dose. Whether the approach extends to other chemotherapy-resistant cancers is open. For a newcomer: a drug that removes a stress-hormone shield so chemotherapy works again.","status":"approved","asOf":"2026-09-04","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relacorilant"}],"tags":[],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer","advanced-adrenocortical-carcinoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["corcept"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07259317","nct06906341"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Lifyorli","modality":"Small-molecule glucocorticoid receptor antagonist","mechanism":"Selective GR antagonist restoring chemosensitivity.","approvals":[{"region":"US","year":2026,"indication":"Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel"}],"mechanismSteps":["Cortisol binds glucocorticoid receptors in tumour cells and switches on anti-apoptotic genes","Relacorilant blocks the glucocorticoid receptor selectively (no progesterone receptor effect)","Pro-survival signalling induced by stress hormones is removed","Tumour cells regain sensitivity to nab-paclitaxel"],"dosing":{"route":"Oral","schedule":"150 mg once daily the day before, day of, and day after each weekly nab-paclitaxel dose (ROSELLA schedule)","monitoring":"Electrolytes, blood pressure, neuropathy","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},"toxicity":[{"event":"Neutropenia"},{"event":"Anaemia"},{"event":"Fatigue"},{"event":"Nausea"},{"event":"Peripheral neuropathy"},{"event":"Hypokalaemia"}],"access":[{"country":"US","reimbursement":"Medicare Part D (oral); commercial plans per formulary, often with prior authorisation","source":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","asOf":"2026-09-06"}],"regulatoryEvents":[{"date":"2025-06","type":"filing","region":"US","note":"NDA submitted (ROSELLA)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2026-Q1","type":"approval","region":"US","note":"Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}]},"route":"/drugs/relacorilant/","neighbours":{"cancer":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"company":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"}],"trial":[{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","route":"/trials/nct06906341/"},{"id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/"},{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/"}],"paper":[{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/"}]}}